详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Neurology State Key Lab of Biotherapy and Cancer center West China Hospital Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu Sichuan China. [2]National Laboratory of Biomacromolecules Chinese Academy of Sciences (CAS) Center for Excellence in Biomacromolecules Institute of Biophysics, Chinese Academy of Sciences Beijing China. [3]Wuxi Biortus Biosciences Co. Ltd. Jiangyin China. [4]School of life and health Kobilka Institute of Innovative Drug Discovery the Chinese University of Hong Kong Shenzhen China. [5]Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China.

出处：

DOI：

摘要：

The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants has posed a serious global public health emergency. Therapeutic interventions or vaccines are urgently needed to treat and prevent the further dissemination of this contagious virus. This study described the identification of neutralizing receptor-binding domain (RBD)-specific antibodies from mice through vaccination with a recombinant SARS-CoV-2 RBD. RBD-targeted monoclonal antibodies (mAbs) with distinct function and epitope recognition were selected to understand SARS-CoV-2 neutralization. High-affinity RBD-specific antibodies exhibited high potency in neutralizing both live and pseudotype SARS-CoV-2 viruses and the SARS-CoV-2 pseudovirus particle containing the spike protein S-RBDV367F mutant (SARS-CoV-2(V367F)). These results demonstrated that these antibodies recognize four distinct groups (I-IV) of epitopes on the RBD and that mAbs targeting group I epitope can be used in combination with mAbs recognizing groups II and/or IV epitope to make mAb cocktails against SARS-CoV-2 and its mutants. Moreover, structural characterization reveals that groups I, III, and IV epitopes are closely located to an RBD hotspot. The identification of RBD-specific antibodies and cocktails may provide an effective therapeutic and prophylactic intervention against SARS-CoV-2 and its isolates.© 2021 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

无

最新[2023]版：

大类 | 3 区医学

小类 | 3 区医学：研究与实验

第一作者：

第一作者机构： [1]Department of Neurology State Key Lab of Biotherapy and Cancer center West China Hospital Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu Sichuan China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Neurology State Key Lab of Biotherapy and Cancer center West China Hospital Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu Sichuan China. [2]National Laboratory of Biomacromolecules Chinese Academy of Sciences (CAS) Center for Excellence in Biomacromolecules Institute of Biophysics, Chinese Academy of Sciences Beijing China. [5]Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology ShanghaiTech University Shanghai China. [*1]andWenqingXu,National Laboratory of Biomacromolecules,ChineseAcademy of Sciences (CAS) Center for Excellence inBiomacromolecules, Institute of Biophysics, ChineseAcademy of Sciences, 100101 Beijing, China. [*2]Department ofNeurology, State Key Lab of Biotherapy and Cancer center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy,Chengdu, Sichuan, 610041 China.

推荐引用方式(GB/T 7714)：

APA：

MLA：